LB Pharmaceuticals Raises $285M in Landmark Biotech IPO

Published on LinkedIn (via Spencer Knight)

LB Pharmaceuticals completed the largest biotech IPO of 2025 to date, raising $285M to advance its oral schizophrenia therapy LB-102 into Phase 3. The offering signals renewed momentum for biotech IPOs and highlights strong investor confidence in neuropsychiatry innovation.

👉 Read the full article: The First Biotech IPO in 7 months

Disclaimer

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link. SSCTR does not provide medical advice, and the views expressed are for educational purposes only.